» Articles » PMID: 29973924

Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection

Overview
Journal Front Microbiol
Specialty Microbiology
Date 2018 Jul 6
PMID 29973924
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Recent experiments have suggested that the infectivity of simian immunodeficiency virus (SIV) and human immunodeficiency virus type-1 (HIV-1) in plasma decreases over time during primary infection. Because anti-gp41 antibodies are produced early during HIV-1 infection and form antibody-virion complexes, we studied if such early HIV-1 specific antibodies are correlated with the decay in HIV-1 infectivity. Using a viral dynamic model that allows viral infectivity to decay and frequent early viral load data obtained from 6 plasma donors we estimate that HIV-1 infectivity begins to decay after about 2 weeks of infection. The length of this delay is consistent with the time before antibody-virion complexes were detected in the plasma of these donors and is correlated ( = 0.023, = 0.87) with the time for antibodies to be first detected in plasma. Importantly, we identify that the rate of infectivity decay is significantly correlated with the rate of increase in plasma anti-gp41 IgG concentration ( = 0.046, = 0.82) and the increase in IgM+IgG anti-gp41 concentration ( = 8.37 × 10, = 0.98). Furthermore, we found that the viral load decay after the peak did not have any significant correlation with the rate of anti-gp41 IgM or IgG increase. These results indicate that early anti-gp41 antibodies may cause viral infectivity decay, but may not contribute significantly to controlling post-peak viral load, likely due to insufficient quantity or affinity. Our findings may be helpful to devise strategies, including antibody-based vaccines, to control acute HIV-1 infection.

Citing Articles

Assessing the impact of autologous neutralizing antibodies on rebound dynamics in postnatally SHIV-infected ART-treated infant rhesus macaques.

Mainou E, Berendam S, Obregon-Perko V, Uffman E, Phan C, Shaw G bioRxiv. 2024; .

PMID: 38895223 PMC: 11185557. DOI: 10.1101/2024.06.01.596971.


Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.

Wu C, Raheem I, Nahas D, Citron M, Kim P, Montefiori D Proc Natl Acad Sci U S A. 2024; 121(22):e2317230121.

PMID: 38768344 PMC: 11145295. DOI: 10.1073/pnas.2317230121.


A Higher-Order Galerkin Time Discretization and Numerical Comparisons for Two Models of HIV Infection.

Attaullah , Yuzbasi S, Alyobi S, Yassen M, Weera W Comput Math Methods Med. 2022; 2022:3599827.

PMID: 36404912 PMC: 9668455. DOI: 10.1155/2022/3599827.


Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines.

Mayer-Blackwell K, Johnson A, Potchen N, Minot S, Heptinstall J, Seaton K Front Immunol. 2022; 13:983313.

PMID: 36311720 PMC: 9597301. DOI: 10.3389/fimmu.2022.983313.


Monocyte Gene and Molecular Expression Profiles Suggest Distinct Effector and Regulatory Functions in Beninese HIV Highly Exposed Seronegative Female Commercial Sex Workers.

Blondin-Ladrie L, Fourcade L, Modica A, Aranguren M, de Montigny N, Labbe A Viruses. 2022; 14(2).

PMID: 35215954 PMC: 8878004. DOI: 10.3390/v14020361.


References
1.
Stafford M, Corey L, Cao Y, Daar E, Ho D, Perelson A . Modeling plasma virus concentration during primary HIV infection. J Theor Biol. 2000; 203(3):285-301. DOI: 10.1006/jtbi.2000.1076. View

2.
Dianzani F, Antonelli G, Riva E, Turriziani O, Antonelli L, Tyring S . Is human immunodeficiency virus RNA load composed of neutralized immune complexes?. J Infect Dis. 2002; 185(8):1051-4. DOI: 10.1086/340043. View

3.
Gasper-Smith N, Crossman D, Whitesides J, Mensali N, Ottinger J, Plonk S . Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol. 2008; 82(15):7700-10. PMC: 2493338. DOI: 10.1128/JVI.00605-08. View

4.
Little S, McLean A, Spina C, Richman D, Havlir D . Viral dynamics of acute HIV-1 infection. J Exp Med. 1999; 190(6):841-50. PMC: 2195636. DOI: 10.1084/jem.190.6.841. View

5.
Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler J . Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet. 1999; 354(9192):1782-5. DOI: 10.1016/S0140-6736(99)02035-8. View